PATENT CLAIM ANALYSIS

Application Number: 15810992
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-05
Patent Classification: ["514", "04400A"]

Abstract:
The present invention relates to a composition for cancer cell sensitization containing as an active ingredient a substance inhibiting the expression of an oncogene of a HPV virus, and more specifically, to a composition for radiosensitization which is used for the treatment of cancer induced by HPV infection and contains as an active ingredient oligonucleotide having any one nucleic acid sequence selected from the group consisting of sequence numbers 1 to 10. The oligonucleotide of the present invention inhibits the expressions of E6 and E7 which are HPV virus oncoproteins, thereby inhibiting the proliferation of tumor cells, and enhances the sensitivity of tumor cells to radiation, thereby exhibiting an excellent effect as a sensitizer that can maximize the cell death effect.

Claim (Index 12):
The method according to  claim 10 , wherein HPV (human papilloma virus)-induced cancer is selected from the group consisting of cervical cancer, vaginal cancer, vulvar cancer, anal cancer, penis cancer, tonsillar cancer, pharynx cancer, laryngeal cancer, head & neck cancer, and adenocarcinoma of lung.

Metadata:
- Claim Count in Document: 23.0
- Percentile: 86.0
- Lexical Diversity: 1.75342
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15632600', '14419234', '13752568', '12513337', '15109879']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8407263703688496
- 35 USC 102 Novelty (BERT): 0.5597947637493678
- Combined Prediction Score: 0.8126332097069013
- Mean Citation Score: 411.97773
- Max Citation Score: 457.97845
- Similarity Product: 351.01520256069296

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test